Evidence map›Paper›PMID 42323702›Full record

ArticlePharmacology research & perspectives2026

Promoting Sustainable Prescribing-A Case Study Presenting Experiences From Two Swedish Drug and Therapeutics Committees.

Björn Ericsson, Ulf Lindahl, Johanna Villén, Marmar Nekoro, Helena Ramström, Björn Wettermark

Abstract read
In one paragraph

Article in Pharmacology research & perspectives, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Björn EricssonGävleborg Drug and Therapeutics Committee, Gävle, Sweden.ORCID https://orcid.org/0009-0008-6710-875X
Ulf LindahlVästernorrland Drug and Therapeutics Committee, Härnösand, Sweden.ORCID https://orcid.org/0009-0001-6188-9240
Johanna VillénDepartment of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0001-9778-0573
Marmar NekoroDepartment of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0009-0007-0326-6137
Helena RamströmHealth and Medical Care Administration, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-5093-6136
Björn WettermarkDepartment of Pharmacy, Faculty of Pharmacy, Uppsala University, Uppsala, Sweden.ORCID https://orcid.org/0000-0003-0531-2516

Funding

Uppsala Universitet 10.13039/501100007051
6 · The paper itself

Abstract

During the past two decades, it has become evident that pharmaceuticals is an emerging environmental problem. In this study, we present the experiences from two Swedish Drug & Therapeutics Committees (DTCs) on how they integrate environmental considerations into their formularies and continuous professional education activities. A cross sectional study was performed describing activities to promote sustainable prescribing conducted during two decades by the DTCs in the Swedish regions of Gävleborg and Västernorrland, along with trends in sales of diclofenac and fluoroquinolones between 2000 and 2024. The two DTCs integrate environmental considerations in their formularies and continuous professional education activities. Further acitivities include monitoring of prescribing, dialogue with water suppliers and pharmacies, as well as information and communication to the general public. The total utilization of diclofenac for systemic use peaked with 127 kg in Gävleborg and 137 kg in Västernorrland in 2011, after which the amounts declined. The topical formulations were mainly sold as over-the-counter and increased until 2016, when it started to decline. The amounts of ciprofloxacin and norfloxacin increased until 2012 when they started to decline. This case study from two Swedish regions illustrates how environmental considerations can be incorporated into the DTC's mission to promote rational and responsible medication use. We believe it may be valuable for different stakeholders to show potential ways in how to promote a more sustainable use of medicines.

Indexed as

Drug PrescriptionsPharmacy and Therapeutics CommitteePractice Patterns, Physicians'CiprofloxacinCross-Sectional StudiesDiclofenacFluoroquinolonesHumansNorfloxacinSwedenCiprofloxacinDiclofenacFluoroquinolonesNorfloxacinDrug and Therapeutics Committeeenvironmentpharmaceutical pollutionprescribingrational drug usesustainabilitySweden

Identifiers

PMID42323702
PMCPMC13283205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.